ESC 365 - GLP-1 receptor agonists: the cardiovascular benefits beyond glucose control.

ESC Premium Access

GLP-1 receptor agonists: the cardiovascular benefits beyond glucose control.

Session: Outcomes of GLP-1 RA in diabetes and cardiovascular disease: what are the key opportunities for cardiology practice? (EBAC Accredited)

Topic: Risk Factors and Prevention

Speaker: Professor F. Krag Knop (Copenhagen, DK)

Organised by PACE-CME, Physicians' Academy for Cardiovascular Education, supported with an educational grant from Novo Nordisk

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Professor Filip Krag Knop

Gentofte Hospital, University of Copenhagen, Copenhagen (Denmark)

4 presentations

0 follower

4 more presentations in this session

Introduction - Outcomes of GLP-1 RA in diabetes and cardiovascular disease: what are the key opportunities for cardiology practice?

Speaker: Professor T. Luescher (London, GB)

Diabetes and cardiovascular disease: time for a multifactorial approach.

Speaker: Professor J. Deanfield (London, GB)

Translating GLP-1 trial outcomes to cardiology practice: which patients will benefit? .

Speaker: Professor L. Ryden (Stockholm, SE)

Discussion and summary - Outcomes of GLP-1 RA in diabetes and cardiovascular disease: what are the key opportunities for cardiology practice?

Speaker: Professor T. Luescher (London, GB) Professor J. Deanfield (London, GB)

Access the full session

Outcomes of GLP-1 RA in diabetes and cardiovascular disease: what are the key opportunities for cardiology practice? (EBAC Accredited)

Speakers: Professor F. Krag Knop, Professor T. Luescher, Professor J. Deanfield, Professor L. Ryden, Professor T. Luescher...

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources